CTAG1A Antibody

說(shuō)明書(shū)

中文名稱(chēng)：

CTAG1A兔多克隆抗體
貨號(hào)：

CSB-PA006125GA01HU
規(guī)格：

￥3,900
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

P78358
基因名：

CTAG1A
別名：

CTAG1A antibody; CTAG1B antibody; Autoimmunogenic cancer/testis antigen NY ESO 1 antibody; Autoimmunogenic cancer/testis antigen NY-ESO-1 antibody; Cancer antigen 3 antibody; Cancer/testis antigen 1 antibody; Cancer/testis antigen 1B antibody; Cancer/testis antigen 6.1 antibody; CT6.1 antibody; CTAG 1 antibody; CTAG 1B antibody; CTAG antibody; CTAG1 antibody; CTAG1B antibody; CTG1B_HUMAN antibody; ESO 1 antibody; ESO1 antibody; L antigen family member 2 antibody; LAGE 2 antibody; LAGE 2 protein antibody; LAGE 2B antibody; LAGE-2 antibody; LAGE2 antibody; LAGE2 protein antibody; LAGE2A antibody; LAGE2B antibody; New York esophageal squamous cell carcinoma 1 antibody; NY ESO 1 antibody; NYESO 1 antibody; NYESO1 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human
免疫原：

Human CTAG1A
免疫原種屬：

Homo sapiens (Human)
抗體亞型：

IgG
純化方式：

Antigen Affinity purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.02% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA,WB
Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

基因功能參考文獻(xiàn)：
1. Twenty-eight out of 38 cancer specimens exhibited NY-ESO-1 protein expression, 2/38 showed a strong universal (4+) NY-ESO-1 staining, and 9/40 cancer lesions exhibited a strong (4+) staining for survivin. PMID: 29058035
2. A significant association was found between AKAP4 gene expression and metastasis (P-value: 0.045), expression of the CTAG1B (NY-ESO-1) gene was not observed in our cases. PMID: 29480665
3. In 22 melanoma patients with stage III lymph node metastasis, overall survival was significantly higher in the XAGE-1b and NY-ESO-1 double-negative group than in the other groups. PMID: 28105694
4. The present results indicate the strong humoral immune response against NY-ESO-1 in natural human T-cell leukemia virus type 1 infection, irrespective of the clinical status. PMID: 28716148
5. some autoantibodies, such as anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers. PMID: 27140836
6. High NY-ESO-1 expression is associated with Lung Cancer. PMID: 27793776
7. Results support the potential utility of NY-ESO-1, PRAME, and MAGEA4 as targets for immunotherapy and as ancillary prognostic parameters in synovial sarcomas. PMID: 27993576
8. Data suggest that only a small fraction of HLA-A*02:01- (HA)-binding ESO peptides are immunogenic, namely those that have high peptide-binding strength and peptide/HA complex stability. This study involved comparison of in silico-predicted and observed cytotoxic T-lymphocyte recognition of tumor antigen epitopes in melanoma patients and transgenic/knockout mice. (ESO = tumor antigen NY-ESO-1) PMID: 28536262
9. These data demonstrate that MAGE-A1-, MAGE-A3-, and NY-ESO-1-specific T cells with antigen-specific cytotoxicity can be cultured from healthy donors and patient-derived cells making adoptive immunotherapy with these cytotoxic T lymphocyte feasible. PMID: 28677424
10. Comparing the overall expression of CTAs, a decreased expression of all melanoma-associated antigens (MAGEs) post-treatment and a slightly increased expression of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) was visible. The simultaneous cytoplasmic and nuclear expression of pan-MAGE or MAGE-A3/A4 correlated with reduced treatment-failure-free-survival (TFFS). PMID: 27466502
11. MAGE-A is more highly expressed than NY-ESO-1 in a majority of human malignancies PMID: 27070449
12. These cells were used to target a human lung cancer line that expressed NY-ESO-1. PMID: 26324743
13. regulation of NY-ESO-1 processing by the ubiquitin receptors Rpn10 and Rpn13 as a well as by the standard and immunoproteasome is governed by non-canonical ubiquitination on non-lysine sites. PMID: 26903513
14. CTAs (MAGE-A4, NY-ESO-1, MAGE-A10) were more likely expressed in patients with squamous cell carcinoma of the lung and when CTAs combined with CD133, they can be better prognostic factors. PMID: 26191258
15. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). PMID: 25412843
16. High expression of NY-ESO-1 is associated with Triple-Negative Breast Cancer. PMID: 26413775
17. NY-ESO-1 expression in melanoma was associated with tumor progression, including increased tumor thickness, and with reduced tumor infiltrating lymphocytes. PMID: 25954764
18. NY-ESO-1 is expressed in esophageal adenocarcinomas, Barrett's metaplasia and normal tissues other than germ cells PMID: 24744590
19. NY-ESO-1 cancer antigen expression has a role in immunotherapy in thyroid cancer PMID: 24811699
20. primary autoantibodies against intracellular MM-specific tumor antigens SSX-2 and NY-ESO-1 are rare but functional in multiple myeloma patients after allogeneic stem cell transplantation PMID: 25078248
21. We have also shown that NY-ESO-1 expression may lead to humoral immune response in patients with meningioma. PMID: 24777967
22. NY-ESO-1 tetramer(+) cells were detected concomitantly with high proportions of Treg but were distinct from the latter and displayed characteristics of TH1 effectors. PMID: 24777968
23. neck squamous cell carcinoma patients showing protein expression of MAGE-A family members or NY-ESO-1 represent a subgroup with an extraordinarily poor survival. PMID: 24482145
24. Our observations indicate a tight link of NY-ESO-1 expression to ERG activation PMID: 24789172
25. NY-ESO-1 and SP17 was not significantly associated with a specific histotype, but high-level GAGE expression was more frequent in squamous cell carcinoma. GAGE expression was demonstrated to be significantly higher in stage II-IIIa than stage I NSCLC. PMID: 24103781
26. NY-ESO-1 appears to be a sensitive and a specific marker for myxoid and round cell liposarcoma among mesenchymal myxoid neoplasms. PMID: 23599152
27. Positive results of immunohistostaining were obtained in 16 (35.6%), 7 (15.6%) and 36 (80.0%) samples using MAGE-C1, NY-ESO-1 and Sp17 antibodies, respectively PMID: 23923079
28. study analyzed NY-ESO-1 expression in 222 melanoma specimens including 16 primary and 206 metastatic tumors; results support previous findings showing higher expression of NY-ESO-1 in metastatic (58/206) versus primary (0/16) tumors; results also show epithelioid subtype of melanoma has the highest incidence of NY-ESO-1 expression PMID: 24290058
29. In two non epithelial cancers (glioma and mesothelioma), the epigenetic regulation of the NY-ESO-1 gene requires the sequential recruitment of the HDAC1-mSin3a-NCOR, Dnmt3b-HDAC1-Egr1 and Dnmt1-PCNA-UHRF1-G9a complexes. PMID: 23312906
30. Melanoma patients' humoral immune systems responded to NY-ESO-1 differently in each individual. PMID: 23454162
31. CTAG1B mRNA and protein are overexpressed with high frequency in myxoid and round cell liposarcoma PMID: 22936067
32. High CTAG1 expression and down-regulation of HLA class-I is associated with non-small cell lung cancer. PMID: 23645764
33. NY-ESO-1 is strongly and diffusely expressed in a majority of synovial sarcomas, but only rarely in other mesenchymal lesions. Suggest roles in targeted therapy and differential diagnosis. PMID: 22388761
34. The presence of circulating T cells responding to Melan-A or NY-ESO-1 had strong independent prognostic impact on survival in advanced melanoma. PMID: 22529253
35. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. PMID: 22323448
36. Polymeric structure and TLR4 may play important roles in rendering NY-ESO-1 immunogenic and thus serve as a potent molecular adjuvant. NY-ESO-1 thus represents the first example of a cancer/testis antigen PMID: 21900253
37. Integrated NY-ESO-1 immune responses may have predictive value for ipilimumab treatment in patients with advanced metastatic melanoma. PMID: 21933959
38. Primary tumors with and without lymph node metastases showed no significant differences in MAGE-A 3/4 (P=0.672) and NY-ESO-1 (P=0.444) expression PMID: 21556122
39. LAGE-1a and NY-ESO-1 homology cannot be easily exploited in an anti-NY-ESO-1 vaccine given the low frequency of protein expression detected by IHC or serum analysis. PMID: 21247062
40. Report immunohistochemical expression of NY-ESO-1 in renal oncocytoma and chromophobe renal cell carcinoma. PMID: 20591578
41. Most melanoma patients with spontaneous NY-ESO-1-specific responses in this study exhibit spontaneous CD4-positive T cell responses to at least one of the three immunodominant LAGE-1 epitopes. PMID: 21131422
42. A versatile prime-boost vaccine strategy allows the generation of powerful, high-avidity tumor-associated immunodominant NY-ESO-1-transgene specific CD8-positive cytotoxic T cell responses. PMID: 20733200
43. tumor antigen NY-ESO-1 has a role in the immune responses to tumor and self-antigens PMID: 20368442
44. ESO 9V peptide isoform is more efficient in inducing conjugate formation and cytolytic granule polarization than the ESO 9L isoform. PMID: 20053942
45. MAGE-A3/6 and NY-ESO-1 were expressed in 50.0% (66/132) and 18.2% (24/132) of non-small-cell lung carcinomas, respectively. PMID: 19795170
46. High NY-ESO-1 expression is associated with oral squamous cell carcinoma. PMID: 20044626
47. Postvaccine T-cell clones are shown to recognize and lyse NY-ESO-1 expressing tumor cell lines in vitro. PMID: 19728336
48. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. PMID: 11782380
49. NY-ESO-1 is a marker that can be used to follow the early progression of testicular tumorigenesiswhen the tumors express a similar pattern to the cells of origin,although later tumors cease to express NY-ESO-1. PMID: 12065688
50. abilities of human monocyte-derived DCs and DCs derived in vitro from CD34-positive stem cells to present NY-ESO-1 epitopes to MHC class I-restricted cytotoxic T cells PMID: 12138174
顯示更多

收起更多
亞細(xì)胞定位：

Cytoplasm.
蛋白家族：

CTAG/PCC1 family
組織特異性：

Expressed in testis and ovary and in a wide variety of cancers. Detected in uterine myometrium. Expressed from 18 weeks until birth in human fetal testis. In the adult testis, is strongly expressed in spermatogonia and in primary spermatocytes, but not in
數(shù)據(jù)庫(kù)鏈接：

HGNC: 24198

OMIM: 300156

KEGG: hsa:1485

STRING: 9606.ENSP00000332602

UniGene: Hs.534310

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human